# Benjamin M. Parsons

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/benjamin-m-parsons/

## Facts

| Field | Value |
| --- | --- |
| Citations | 4,684 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 27 |
| i10-index | 41 |
| Last Known Institution | Gundersen Health System |
| OpenAlex ID | https://openalex.org/A5016540674 |
| ORCID iD | 0000-0002-5634-2937 |
| Works | 253 |

## Researcher papers

- [Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial](https://scholariq.org/papers/pembrolizumab-in-patients-with-advanced-hepatocellular-carcinoma-previously/)
- [Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial](https://scholariq.org/papers/carfilzomib-or-bortezomib-in-combination-with-lenalidomide-and-dexamethasone-for/)
- [A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era](https://scholariq.org/papers/a-retrospective-multicenter-analysis-of-elderly-hodgkin-lymphoma-outcomes-and/)
- [Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy](https://scholariq.org/papers/consensus-recommendations-on-the-management-of-toxicity-associated-with-cd3-cd20/)
- [Prognostic impact of concurrent <i>MYC</i> and <i>BCL6</i> rearrangements and expression in <i>de novo</i> diffuse large B-cell lymphoma](https://scholariq.org/papers/prognostic-impact-of-concurrent-i-myc-i-and-i-bcl6-i-rearrangements-and/)
- [Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma](https://scholariq.org/papers/assessment-of-cd37-b-cell-antigen-and-cell-of-origin-significantly-improves-risk/)
- [Analysis of very elderly (≥80 years) non‐hodgkin lymphoma: impact of functional status and co‐morbidities on outcome](https://scholariq.org/papers/analysis-of-very-elderly-80-years-non-hodgkin-lymphoma-impact-of-functional/)
- [Intravascular large B-cell lymphoma in the United States (US): a population-based study using Surveillance, Epidemiology, and End Results program and National Cancer Database*](https://scholariq.org/papers/intravascular-large-b-cell-lymphoma-in-the-united-states-us-a-population-based/)
- [Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium](https://scholariq.org/papers/primary-testicular-diffuse-large-b-cell-lymphoma-displays-distinct-clinical-and/)
- [Clinical and Biologic Significance of <i>MYC</i> Genetic Mutations in <i>De Novo</i> Diffuse Large B-cell Lymphoma](https://scholariq.org/papers/clinical-and-biologic-significance-of-i-myc-i-genetic-mutations-in-i-de-novo-i/)
- [A Reappraisal of the Comparative Effectiveness of Lumpectomy Versus Mastectomy on Breast Cancer Survival: A Propensity Score–Matched Update From the National Cancer Data Base (NCDB)](https://scholariq.org/papers/a-reappraisal-of-the-comparative-effectiveness-of-lumpectomy-versus-mastectomy/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Radiomics and Machine Learning in Medical Imaging](https://scholariq.org/topics/radiomics-and-machine-learning-in-medical-imaging/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)

## Researcher university

- [Gundersen Health System](https://scholariq.org/institutions/gundersen-health-system/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.